If You Invested in MIRA Pharmaceuticals, Inc. (MIRA)

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) is a clinical-stage biopharmaceutical company focused on developing novel oral and topical therapeutics for neurologic, neuropsychiatric, metabolic, and pain-related disorders. According to its SEC filings, MIRA is incorporated in Florida and maintains principal executive offices in Miami, Florida. The company operates in the medicinal and botanical manufacturing space within the broader manufacturing sector, with a pipeline that targets high-unmet-need indications such as neuropathic pain, chronic inflammatory pain, obesity, nicotine addiction, and post-traumatic stress disorder (PTSD).

Core Pipeline and Therapeutic Focus

MIRA’s development strategy centers on differentiated, non-opioid and non-controlled drug candidates designed to address limitations of existing therapies. Following the acquisition of SKNY Pharmaceuticals, Inc., described in a Form 8-K filed on September 30, 2025, MIRA positions itself as a multi-program biopharmaceutical developer with several key programs:

• Ketamir-2 – a proprietary, orally bioavailable new molecular entity described as a next-generation ketamine analog. SEC and news disclosures state that Ketamir-2 selectively targets the NMDA receptor (PCP site) with low affinity and shows no significant off‑target activity across a broad receptor panel. It is being developed primarily for neuropathic pain, with additional preclinical activity reported in depression and PTSD.
• MIRA-55 – an oral, cannabis- or marijuana-derived analog (described as an oral THC or marijuana analog and a non‑psychotropic marijuana analog in SEC filings) with preclinical results in inflammatory and nociceptive pain, as well as activity in cognitive decline and anxiety. MIRA-55 is designed to provide analgesic and anti‑inflammatory benefit without the addictive risk or psychoactive side effects associated with traditional THC or opioids.
• SKNY-1 – an oral therapeutic candidate obtained through the SKNY acquisition, targeting obesity and smoking cessation. SEC filings describe SKNY-1 as a differentiated oral drug candidate with preclinical results demonstrating up to 30% weight loss without muscle loss and reversal of nicotine craving.

Ketamir-2: Neuropathic Pain and CNS Disorders

Multiple SEC filings and company news releases describe Ketamir-2 as MIRA’s lead oral candidate in neuropathic pain. The U.S. Food and Drug Administration cleared an Investigational New Drug (IND) application for Ketamir-2 for neuropathic pain, enabling U.S. clinical trials. A Form 8-K dated September 22, 2025, reports favorable topline results from the single ascending dose (SAD) portion of a Phase 1 trial in healthy volunteers, noting that Ketamir-2 was generally safe and well tolerated across all dose levels, with no dose‑limiting toxicities or serious adverse events and no clinically significant central nervous system adverse effects.

The same filing details pharmacokinetic findings, including dose‑proportional exposure, rapid absorption, and a duration of action that supports once‑daily dosing. Additional 8-K and news disclosures state that the multiple ascending dose (MAD) portion of the Phase 1 study has been initiated, with chemotherapy‑induced peripheral neuropathy (CIPN) selected as the lead indication for planned Phase 2a evaluation. Preclinical data summarized in SEC and news documents indicate that Ketamir-2 outperformed ketamine, gabapentin, and pregabalin in several gold‑standard rodent models of neuropathic pain, including chemotherapy‑induced and sciatic nerve ligation models, and that it produced near‑complete normalization of pain sensitivity in certain chemotherapy‑induced neuropathy models.

Beyond pain, SEC filings and news reports describe preclinical studies in which Ketamir-2 demonstrated activity in PTSD and depression. In a validated Single Prolonged Stress (SPS) model of PTSD in rats, Ketamir-2 restored behavior toward non‑stressed levels. The U.S. Drug Enforcement Administration’s scientific review, as cited in multiple filings, concluded that Ketamir-2 would not be considered a controlled substance or listed chemical under the Controlled Substances Act.

MIRA-55: Chronic Inflammatory and Nociceptive Pain

MIRA-55 is described in SEC filings as an oral THC or marijuana analog and a proprietary non‑psychotropic marijuana analog. The company reports preclinical data in inflammatory and nociceptive pain models showing that MIRA-55 achieved pain relief comparable to, and in some studies superior to, injected morphine. An 8-K dated October 15, 2025, states that oral MIRA-55 normalized pain thresholds and significantly reduced inflammation in a formalin‑induced chronic inflammatory pain model, outperforming injected morphine in reversing pain sensitivity and reducing paw edema.

These data support MIRA’s plan, as disclosed in SEC filings, to pursue an Investigational New Drug application for chronic inflammatory pain. The company also notes preclinical activity of MIRA-55 in cognitive decline and anxiety, and emphasizes its design to provide benefit without addictive risk or THC‑related psychoactive side effects.

SKNY-1: Obesity and Nicotine Addiction

Through the completed acquisition of SKNY Pharmaceuticals, documented in the September 30, 2025 Form 8-K, MIRA added SKNY-1 to its pipeline. SEC and news disclosures describe SKNY-1 as a next‑generation oral therapy candidate targeting obesity and smoking cessation. Preclinical studies cited by the company indicate up to 30% body weight reduction in animal models with preservation of muscle mass, as well as reversal of nicotine craving and high‑calorie food cravings.

Filings also note that SKNY-1 is designed to modulate CB1, CB2, and MAO‑B pathways and to address appetite, reward, and craving while seeking to avoid the psychiatric side effects that limited earlier CB1‑targeting drugs. Mechanistic work referenced in news reports indicates biased CB1 signaling intended to reduce food intake and body weight while improving central nervous system safety compared with prior agents in this class.

Regulatory and Clinical Development Strategy

MIRA’s SEC filings outline a development path that includes:

• Phase 1 SAD and MAD studies of oral Ketamir-2 in healthy volunteers, with plans for Phase 2a trials in neuropathic pain and a lead focus on chemotherapy‑induced peripheral neuropathy.
• Preclinical and IND‑enabling work for MIRA-55 in chronic inflammatory pain, supported by animal data showing dual analgesic and anti‑inflammatory effects.
• Integration and advancement of SKNY-1 toward IND‑enabling studies in obesity and nicotine addiction following the SKNY acquisition.
• Additional preclinical programs targeting cognitive impairment and related neuropsychiatric disorders, as referenced in company news.

According to SEC disclosures, MIRA also continues to use at‑the‑market equity offerings and other capital‑raising activities to support its development programs and has taken steps to address Nasdaq listing requirements related to stockholders’ equity.

Corporate Structure and Exchange Listing

Form 8-K filings identify MIRA Pharmaceuticals, Inc. as a Florida corporation with Commission File Number 001‑41765 and an IRS Employer Identification Number 85‑3354547. The company’s common stock trades on The Nasdaq Stock Market under the symbol MIRA. Filings also describe shareholder approvals of equity incentive plan amendments and the SKNY acquisition, as well as compensation and incentive arrangements for senior leadership tied to milestones such as clinical progress, capital‑raising, and completion of strategic transactions.

Business Model and Therapeutic Areas

Based on its SEC and news disclosures, MIRA’s business model is centered on discovering, acquiring, and developing novel small‑molecule therapeutics that target:

• Neuropathic pain, including chemotherapy‑induced and other neuropathic conditions, through Ketamir-2.
• Chronic inflammatory and nociceptive pain via MIRA-55.
• Metabolic and addiction disorders such as obesity and nicotine dependence through SKNY-1.
• Neuropsychiatric disorders, including PTSD and depression, where preclinical data support further evaluation of Ketamir-2.

The company emphasizes non‑opioid, non‑addictive mechanisms and, where applicable, non‑controlled status under DEA review as key attributes of its pipeline assets.

Risk and Regulatory Considerations

As a clinical-stage biopharmaceutical company, MIRA’s programs remain subject to the inherent risks of drug development, including clinical trial outcomes and regulatory review. The company’s SEC filings reference ongoing interactions with regulators such as the FDA and DEA, as well as Nasdaq’s monitoring of listing rule compliance. Investors and other stakeholders typically review MIRA’s periodic reports and current reports on Form 8-K for detailed risk factor discussions and updates on development milestones.